Just my .02, but I was thinking about the patient that was mentioned in August and here we are in December. There has to be an update coming any day now, whether it be at the shareholder meeting or PR. The patient had Thymoma, a rare cancer and saw a 6% tumor reduction and he had been on it for 11 months if Im not mistaken so now with additional months and increased doses we should really be able to see how powerful kevetrin really is. ***Additionally, since its rare we could see another Orphan drug designation down the line.

The patient, now in his eleventh month of treatment, is being treated with Kevetrin for Stage 4 thymoma, a rare disease in which cancer cells form on the outside surface of the thymus. The patient’s disease is considered stabilized, as information to date shows a slight reduction (approximately 6 percent) in tumor size. The patient reports feeling better than before and side effects have been minimal. - See more at: http://cellceutix.com/cellceutixs-kevetrin-an...hvs8g.dpuf

http://cellceutix.com/cellceutixs-kevetrin-an...hvs8g.dpbs

http://www.cancer.gov/types/thymoma/patient/t...atment-pdq

Ai

FOR SCOTTSHIT: GOCTIX!!!!